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a b s t r a c t
Avian reovirus non-structural protein muNS is partially cleaved in infected chicken embryo ﬁbroblast
cells to produce a 55-kDa carboxyterminal protein, termed muNSC, and a 17-kDa aminoterminal
polypeptide, designated muNSN. In this study we demonstrate that muNS processing is catalyzed by a
caspase 3-like protease activated during the course of avian reovirus infection. The cleavage site was
mapped by site directed mutagenesis between residues Asp-154 and Ala-155 of the muNS sequence.
Although muNS and muNSC, but not muNSN, are able to form inclusions when expressed individually in
transfected cells, only muNS is able to recruit speciﬁc ARV proteins to these structures. Furthermore,
muNSC associates with ARV factories more weakly than muNS, sigmaNS and lambdaA. Finally, the
inhibition of caspase activity in ARV-infected cells does not diminish ARV gene expression and
replication, but drastically reduces muNS processing and the release and dissemination of progeny
viral particles.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Avian reoviruses (ARVs) are important pathogens that cause
great economic losses in the poultry industry. Infection by these
viruses has been associated with a variety of disease conditions,
including viral arthritis, chronic respiratory diseases, and malab-
sorption syndrome (Jones, 2000; van der Heide, 2000). ARVs are
members of the Orthoreovirus genus, one of the 12 genera of the
Reoviridae family. They are non-enveloped fusogenic viruses
whose particles contain 10 double-stranded RNA genome seg-
ments enclosed within two concentric protein shells (Benavente
and Martinez-Costas, 2007). Viral genomic segments can be
separated electrophoretically into three different size classes,
named L (Large; three segments), M (Medium; three segments)
and S (Small; four segments). The ARV genome expresses at least
8 structural and four non-structural proteins (Bodelon et al., 2001),
but the protein repertoire of ARV is increased to at least 12
structural proteins and six non-structural proteins by post-
translational cleavage of some viral proteins (Busch et al., 2011;
Ji et al., 2010; Varela et al., 1996).
Genome replication and assembly of ARVs takes place in
distinctive cytoplasmic globular inclusions called viral factories
where viral components concentrate to increase the efﬁciency of
these processes (Benavente and Martinez-Costas, 2006; Touris-
Otero et al., 2004a). The framework of the factories is thought to
be formed by the non-structural muNS protein, because it is the
only viral protein that accumulates in factory-like inclusions when
expressed individually in transfected cells (Touris-Otero et al.,
2004b). Furthermore, the fact that viral core protein lambdaA
and the non-structural protein sigmaNS redistribute to inclusions
when individually co-expressed with muNS in transfected cells
suggests that muNS is able to recruit these proteins to viral
factories of infected cells (Touris-Otero et al., 2004a).
Similar to many other viruses, ARVs induce apoptotic cell death
of infected cells, and the activation of the intracellular apoptotic
program takes place during an early stage of the ARV life cycle
(Labrada et al., 2002). Apoptosis is triggered by ARV in the absence
of viral gene expression, but is no longer induced when intracel-
lular viral uncoating is blocked, suggesting both that apoptosis
does not depend on viral protein synthesis and that it is triggered
from within the infected cell by viral products generated after
intraendosomal uncoating of parental reovirions (Labrada et al.,
2002). A previous report revealed that the M3 gene of ARV
expresses three muNS isoforms in infected cells and that the two
smaller isoforms originate by a speciﬁc post-translational cleavage
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near the amino terminus of muNS. This cleavage produces a 55-kDa
carboxyterminal protein, termed muNSC, and a complementary
17-kDa aminoterminal polypeptide, designated muNSN. Cleavage
of muNS occurs with 30% efﬁciency, so precursor muNS and
its cleavage products are all present in ARV-infected cells (Busch et
al., 2011). In this study we show that muNS processing is indirectly
promoted by ARV infection through activation of an effector
caspase that cleaves muNS between amino acid residues 154
and 155.
Results
Cleavage of ARV muNS is promoted by ARV infection
We have previously shown that ARV muNS is cleaved in ARV-
infected cells to produce the aminoterminal peptide muNSN and
the carboxyterminal protein muNSC (Busch, et al., 2011). To assess
whether muNS cleavage is promoted by avian reovirus proteins
and/or by changes induced in the host during infection, we
compared muNS-to-muNSC conversion in ARV-infected cells with
that in transfected cells and in insect cells infected with a muNS-
expressing recombinant baculovirus (Fig. 1A). For this, extracts from
CEF monolayers either mock-infected (lane 1) or infected with ARV
S1133 (lane 2), from CEF monolayers transfected with either empty
pCINeo plasmid (lane 3) or pCINeo–muNS plasmid (lane 4), and
from Sf9 cells infected with either wild-type baculovirus (lane 5)
or recombinant baculovirus AcNPV–S1133–muNS (lane 6) were
subjected to immunoprecipitation (upper panel) and immunoblot
(lower panel) analyses. The results revealed that while a signiﬁcant
amount of muNSC was generated in ARV-infected cells (its position is
marked with an asterisk at the left of lane 2), this protein was hardly
detected in transfected cells (lane 4) or in insect cells infected with a
muNS-expressing recombinant baculovirus (lane 6). These data
strongly suggest that intracellular processing of muNS is promoted
by ARV infection.
Two additional experiments were subsequently performed to
conﬁrm this suggestion. In the ﬁrst one, a plasmid expressing GFP
fused to the amino terminus of muNS (GFP-muNS) was lipofected
into CEF monolayers and 10 h later the monolayers were mock-
infected or infected with ARV S1133 for 16 h. Extracts from these
cells were analyzed by Western blotting using antibodies speciﬁc
for both muNS and GFP. The results shown in Fig. 1B reveal that
while cleavage products derived from GFP-muNS are not detected
in mock-infected cells (lanes 1 and 3), a 45-kDa polypeptide that
is recognized by antibodies against both GFP and muNS is present
in ARV-infected cells (lanes 2 and 4). Its electrophoretic mobility
and its capacity to interact with the two antibodies suggest that
this polypeptide is GFP–muNSN. In the second conﬁrmation experi-
ment (Fig. 1C), 35S-labeled in-vitro-generated muNS (lane 2) was
incubated with extracts obtained from either mock-infected cells
(lane 3) or ARV-infected cells (lane 4), and the resulting samples,
as well as radiolabeled extracts from ARV-infected CEF that had
been immunoprecipitated against muNS (lane 1), were analyzed
by SDS-PAGE and autoradiography. The results revealed that
muNS-to-muNSC conversion took place in the sample incubated
Fig. 1. Proteolytic processing of muNS occurs in ARV-infected cells, but not in transfected or baculovirus-infected cells. (A) CEF monolayers are either mock-infected (lane 1)
or infected with 10 PFU/cell of ARV S1133 (lane 2) for 16 h. The same cells are transfected with either an empty pCINeo3.1 plasmid (lane 3) or with pCINeo-muNS plasmid
(lane 4) for 24 h. Sf9 insect cells are infected with either wild-type baculovirus (lane 5) or with recombinant baculovirus AcNPV-S1133-muNS (lane 6) for two days. The cells
in the upper panel are incubated for 1 h with 100 μCi/ml of [35S]amino acids, then lysed with RIPA buffer and immunoprecipitated with muNS-speciﬁc antiserum.
An immunoblot analysis of nonradiolabeled samples is shown in the lower panel. (B) CEF monolayers are transfected with GFP-muNS for 10 h and then mock-infected
(lanes 1 and 3) or infected with 10 PFU/cell of ARV S1133 for 16 h (lanes 2 and 4). The cells are then lysed in RIPA buffer and analyzed by Western blot with polyclonal
antibodies against both GFP (lanes 1 and 2) and muNS (lanes 3 and 4). (C) 35S-radiolabeled in-vitro-synthesized muNS (lane 2) is incubated for 2 h at 37 1C with extracts from
mock-infected cells (lane 3) or from ARV-infected cells (lane 4). These samples, as well as an immunoprecipitated extract of ARV-infected CEF (lane 1), are analyzed by 10%
SDS-PAGE and autoradiography. Positions of protein markers are indicated on the left, and those of nonstructural ARV proteins on the right. The position of the muNSC band
is marked with an asterisk. (D) Western blot analysis of extracts from CEF monolayers either mock-infected (lane 1) or infected for 16 h with 10 PFU/cell of the ARV isolates
1733 (lane 2), 2408 (lane 3), and S1133 (lane 4). In lane 5 the analysis is performed with an extract of Vero cells infected for 24 h with 50 PFU of ARV S1133, and in lane 6 with
an extract of DF-1 cells infected for 16 h with 10 PFU of ARV S1133. The membranes in lanes 1–4 and 6 are exposed for 5 s and the one in lane 5 for 30 s.
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with extracts from ARV-infected cells (lane 4), but not in the one
incubated with extracts from mock-infected cells (lane 3). Taken
together, these results indicate that muNS cleavage is promoted by
ARV infection.
ARV-triggered apoptosis causes muNS processing
The muNS protein expressed by three different ARV isolates is
processed to a similar extent in infected CEF cells (Fig. 1D, lanes 2–
4), indicating that muNS processing is not a unique property of the
ARV S1133 isolate, but a more general property of ARVs. To assess
whether muNS cleavage is inﬂuenced by cell-type speciﬁc factors
we examined muNS-to-muNSC conversion in cells other than CEF.
The results revealed that partial cleavage of ARV muNS also took
place in ARV-infected monkey Vero cells (Fig. 1D, lane 5) and in
human HeLa cells (Fig. 5A, lane 2). Surprisingly, the load of muNSC
is highly reduced following infection with ARV S1133 of the CEF-
derived avian cell line DF-1 (Fig. 1D, lane 6), suggesting that muNS
processing is controlled by cell factors.
The immortal DF-1 cell line was established spontaneously
from Line 0 endogenous-virus negative embryos and had been
widely used for the propagation of various avian viruses (Bacon et
al., 2000). A genome-wide transcription proﬁle of DF-1 cells and a
comparison of their global gene expression with that of primary
CEF revealed that DF-1 cells are characterized by enhanced
molecular mechanisms for cell cycle progression and proliferation,
suppressing cell death pathways, downregulation of caspase 3,
altered cellular morphogenesis, and accelerated capacity for mole-
cule transport (Kong et al., 2011). The observation that reduced
caspase activity of DF1 cells is accompanied by diminished muNS
processing when ARV infects these cells raised the interesting
possibility that caspase activation and muNS cleavage are inter-
linked events. This hypothesis is reinforced by our ﬁnding that
muNS is not processed when expressed in baculovirus-infected
cells (Fig. 1A), probably because baculoviruses express anti-
apoptotic factors that prevent caspase activation (Clem, 2007;
Clem et al., 1991), although this awaits experimental conﬁrmation.
To explore whether there was a connection between caspase
activity and muNS processing we ﬁrst investigated the effect that
two broad-spectrum caspase inhibitors, Z-VAD-FMK and Q-VD-
OPh, exert on these processes when added to ARV-infected cells at
the onset of infection. The effect of these inhibitors on the
apoptotic state of infected cells was monitored by two different
approaches. In the ﬁrst one, we used immunoﬂuorescence analysis
of histone H2AX phosphorylation to determine the percentage of
cells containing damaged DNA (Cook et al., 2009; Yuan et al.,
2010). For this, the cells were ﬁxed, stained with a monoclonal
antibody against phosphorylated H2AX and counterstained with
DAPI. Polyclonal antiserum against the nonstructural muNS
protein was also used to visualize ARV-infected cells (Fig. 2A).
Quantiﬁcation of the stained cells revealed that, similar to staur-
osporine treatment (lane 5), ARV infection caused a 10 fold
increase in the percentage of cells containing phosphorylated
H2AX (compare lanes 1 and 4). However, this increase was highly
Fig. 2. Effect of apoptosis inhibitors on muNS processing. (A) Effect of apoptotic inhibitors on DNA damage. CEF monolayers are infected with 10 PFU/cell of ARV in the
absence (lane 1) or presence of either 100 μM Z-VAD-FMK (Z; lane 2) or 10 μM Q-VD-OPh (Q; lane 3). Mock-infected cells either untreated (lane 4) or incubated for 6 h in the
presence of 0.5 μM staurosporine (lane 5) are used as control samples. The cells are analyzed by indirect immunoﬂuorescence with rabbit polyclonal antibodies against
muNS (upper row; green), with a monoclonal antibody against phosphorylated H2AX (middle row; red), and nuclei are stained with DAPI (lower row; blue). The percentage
of red-stained nuclei shown at the bottom of the ﬁgure is the mean of three independent experiments, and 100 cells were counted for each experiment. (B) Effect of the same
concentrations of the two apoptotic inhibitors on caspase 3/7 activity. Caspase activity is determined with the Caspase-Glos 3/7 Assay kit (Promega), as described inMethods
section, and expressed as arbitrary RLU units. Each value is the mean of three independent experiments. (C) Effect of the two apoptotic inhibitors on muNS processing in
ARV-infected CEF. Processing is monitored by both immunoprecipitation (IP; upper panel) and Western blotting (WB; lower panel) using muNS-speciﬁc antiserum. The
sample in lane 1 is run on the same gel, but an internal lane is removed. (D) Effect of Q-VD-OPh on muNS processing and caspase 3/7 activity. ARV-infected CEF monolayers
are incubated from the onset of the infection with the concentrations of the pancaspase inhibitor shown on top. At 16 hpi the cells are lysed and the resulting extracts are
assayed for caspase 3/7 activity and muNS processing. Processing of muNS is monitored by Western blotting with polyclonal antibodies against muNS and actin. The values of
caspase activity shown at the bottom of the ﬁgure are the mean of three independent experiments. (E) Time course of muNS processing and caspase 3/7 activity in ARV-
infected CEF cells. CEF cell monolayers are infected with 10 PFU/cell of ARV, either in the absence (top blot) or presence (bottom blot) of 10 μM Q-VD-OPh. The cells are lysed
at the infection times indicated at the top of the ﬁgure. The extracts are subsequently processed for both immunoblotting and caspase 3/7 activity, as for Fig. 2D.
J. Rodríguez-Grille et al. / Virology 462-463 (2014) 49–59 51
attenuated when the infected cells were incubated in the presence
of either of the two caspase inhibitors (lanes 2 and 3). In the
second approach, we used the luminiscent Caspase-Glo 3/7 Assay
kit (Promega) for measuring caspase-3/7 activities. The cells were
lysed in Caspase-Glo 3/7 substrate and protease activity was
measured as relative light units (RLU). The results shown at the
bottom of Fig. 2B indicate that infection of CEF cells with ARV
induces a 10 fold increase in caspase activity, but this increase is
signiﬁcantly reduced when the infected cells are incubated in the
presence of either of the two pancaspase inhibitors.
Once demonstrated that the two inhibitors were highly efﬁ-
cient in preventing ARV-induced caspase activation, we next
examined their capacity to prevent muNS processing in ARV-
infected cells. Both immunoblotting and immunoprecipitation
analyses of extracts from ARV-infected CEF revealed that muNS-
to-muNSC conversion was dramatically reduced when the cells
were incubated in the presence of either of the two inhibitors
(Fig. 2C, compare lane 1 with lanes 2 and 3). In subsequent
experiments we exclusively used the inhibitor Q-VD-OPh because
it blocks apoptosis at very low nontoxic concentrations, and also
because it inhibits caspase activity, but not cathepsin activity
(Caserta et al., 2003; Kuželová et al., 2011). The results shown in
Fig. 2D reveal that the ability of Q-VD-OPh to inhibit both
apoptosis and muNS processing in ARV-infected CEF is dose-
dependent, and further show that the load of muNSC is drastically
reduced at a Q-VD-OPh concentration as low as 5 μM. A time
course of muNS processing and caspase activation performed in
ARV-infected cells in the presence or absence of Q-VD-OPh
(Fig. 2E) revealed that even though the presence of muNS was
ﬁrst detected at 3 hpi, muNSC was not detected until 6 hpi,
coinciding with a large increase in caspase 3/7 activity. Further-
more, both muNS processing and an increase in caspase activity
were not observed when Q-VD-OPh was present during the
infection (Fig. 2E, þQ). Taken together, these results strongly
suggest that there is a correlation between ARV-induced apoptosis
and muNS processing.
To conﬁrm this suggestion additional experiments were per-
formed. We ﬁrst observed that the capacity of extracts of ARV-
infected cells to cleave in-vitro-synthesized muNS was largely
abolished when the infected cells were incubated in the presence
of Q-VD-OPh (Fig. 3A, compare lanes 1 and 2). In addition, the
reduced ability of ARV to induce muNS processing in DF-1 cells
was signiﬁcantly enhanced when the cells were incubated during
the last 6 h of infection with the pro-apoptotic agents actinomycin
D and staurosporine (Fig. 3B, compare lane 1 with lanes 2 and 4),
but the ability of these compounds to enhance muNS processing
was blocked in the presence of the apoptotic inhibitor Q-VD-OPh
(Fig. 3B, lanes 3 and 5). Finally, these pro-apoptotic agents were
also effective in promoting muNS processing in transfected cells
(Fig. 3C). Our ﬁndings that caspase inhibitors prevent muNS
processing in ARV-infected cells and that apoptosis enhancers
promote muNS cleavage in both transfected cells and ARV-infected
DF1 cells indicate that muNS cleavage is catalyzed by an effector
caspase activated during ARV infection.
Mapping the muNS cleavage site
In a ﬁrst attempt to map the muNS cleavage site we compared
the electrophoretic mobility of muNSC with that of several muNS
amino-terminal truncations whose translation initiates at different
internal methionine codons (Fig. 4A). Plasmids expressing these
truncations (lanes 3–5) and full-length muNS (lane 2) were
transfected into CEF and the transfected cells, as well as ARV-
infected CEF (lane 1), were incubated with [35S]amino acids at 24 h
after transfection or 16 hpi. The cells were lysed with RIPA buffer,
the extracts were immunoprecipitated with muNS-speciﬁc anti-
serum and the resulting samples were analyzed by SDS-PAGE and
autoradiography. The results reveal that muNSC migrates slightly
faster than the muNS truncation 140–635, suggesting that the
cleavage site should be located several residues downstream of
Met-140 (Fig. 4A). A similar conclusion has been recently reached
when comparing the electrophoretic mobility of muNSC with that
of in-vitro-translated muNS truncations (Busch et al., 2011).
A survey of the deduced amino acid sequence downstream of
Met-140 for an appropriate caspase cleavage motif revealed the
presence of the sequence 151DSPD↓A155 (Fig. 4B, underlined),
which is a canonical cleavage motif for caspases 3 and 7 (DXXD↓Y;
“X” indicates any amino acid; “Y” indicates G, A, T, S or N)
(Thornberry et al., 1997; Timmer and Salvesen, 2007). To verify
that this putative caspase recognition sequence is a bona ﬁde
cleavage site we ﬁrst examined whether the electrophoretic
mobility of muNS, muNSC and muNSN matched with that of
transiently expressed polypeptides comprising muNS residues 1–635,
Fig. 3. Effect of apoptosis inhibitors/enhancers on muNS processing. (A) Effect of
Q-VD-OPh on muNS processing. 35S-radiolabeled in-vitro-synthesized muNS is
incubated for 4 h at 37 1C with extracts from ARV-infected cells that have been
incubated (lane 2) or not (lane 1) with 10 μM Q-VD-OPh from the onset of the
infection. These samples, as well as an extract of ARV-infected CEF immunopreci-
pitated against muNS (lane 3), are analyzed by 10% SDS-PAGE and autoradiography.
(B) Effect of apoptotic enhancers and inhibitors on muNS processing and apoptosis
in DF1 cells. DF-1 cell monolayers are infected with 10 PFU/cell of ARV S1133. The
cells in lanes 3 and 5 are treated at the onset of the infection with 10 μMQ-VD-OPh.
The cells in lanes 2 and 3 are treated from 10 to 16 hpi with 1 μg/ml actinomycin D,
and in lanes 4 and 5 with 0.5 μM staurosporine. Caspase 3/7 activity, DNA damage
and muNS processing are determined at 16 hpi as for Fig. 2A–C. (C) Effect of
apoptotic enhancers and inhibitors on muNS processing in transfected cells. CEF
monolayers are transfected with the pCINeo-muNS plasmid and 24 h later the cells
are incubated for 6 h with the same compounds as for Fig. 3B. The cells are then
lysed and the resulting extracts subjected to Western blot analysis with anti-muNS
serum. The positions of nonstructural viral proteins are indicated on the left and
that of protein markers on the right.
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155–365 and 1–154, respectively (Fig. 4C). ARV-infected CEF (lanes
1 and 6), as well as cells lipofected with empty plasmid (lane 2) or
with plasmids expressing the muNS sequences depicted on top of
Fig. 4C (lanes 3–5), are radiolabeled with [35S]amino acids and
lysed in RIPA buffer. The resulting extracts were immunoprecipi-
tated with polyclonal anti-muNS serum and the imunoprecipi-
tated proteins were resolved on an electrophoresis gel system (8%
tricine–SDS-PAGE gel) speciﬁcally designed to resolve small pep-
tides (Schägger, 2006). The results reveal that the muNS, muNSC
and muNSN proteins present in ARV-infected cells (Fig. 4C, lane 1)
have the same electrophoretic mobility as that of the muNS-
derived recombinant polypeptides comprising residues 1–635,
155–635 and 1–154, respectively (Fig. 4C, lanes 3–5). It should
be however noted that partial conversion of muNS to muNSC took
place in transfected CEF cells when the cell monolayers were kept
in serum-free medium for more than 5 h during lipofection
(Fig. 4C, lane 3). This is probably due to the fact that apoptosis is
induced when the cells are incubated for long periods of time in
serum-free medium (not shown).
To conﬁrm that muNS is cleaved after Asp-154 we next
mutated this residue to Ala and investigated abrogation of clea-
vage. To rule out the possibility that a function of the protein other
than proteolysis could be modiﬁed by the mutation, we examined
the capacity of the D154A mutant to form inclusions and to recruit
the viral proteins lambdaA and sigmaNS to these structures. The
immunoﬂuorescent images shown in Fig. 4D reveal that the single
site mutant D154A maintains the ability of wild-type muNS to
form inclusions (lane 1) and to recruit the two ARV proteins to
these structures (compare top and bottom rows of lanes 2 and 3).
These observations suggest that the D-to-A mutation does not
signiﬁcantly alter the spatial conformation and activity of the
nonstructural viral protein. We next compared the capacity of
staurosporine to promote processing of both wild-type muNS and
its D154A mutant in transfected cells. The results revealed that
staurosporine promoted the cleavage of wild-type muNS, but not
of the mutant D154A, in transfected cells (Fig. 4E). Similarly,
extracts of ARV-infected CEF promoted the cleavage of wild-type
muNS, but not of the D154A mutant (Fig. 4F). Taken together, these
observations indicate that ARV muNS is cleaved by caspases
between muNS residues Asp-154 and Ala-155.
muNS cleavage is catalyzed by a caspase 3-like protease
The results presented so far indicate both that muNS cleavage is
catalyzed by a caspase and that caspase 3 and/or caspase 7 are
activated in ARV infected cells. Our observation that muNS
Fig. 4. Mapping the muNS cleavage site. (A) CEF monolayers are infected with ARV S1133 (lane 1) or lipofected with plasmids expressing muNS versions comprising the
residues shown on top of lanes 2–5. The cells are incubated with [35S]amino acids for 1 h at 16 hpi or for 2 h at 24 h after transfection, and then lysed with RIPA buffer. The
resulting extracts are immunoprecipitated with muNS-speciﬁc antiserum and the samples are analyzed by 8% SDS-PAGE and autoradiography. The position of a non-speciﬁc
protein band in transfected cells is marked with an arrow. (B) Deduced amino acid sequence of the ARV S1133 muNS region comprising residues 140–177. A potential
consensus cleavage sequence for caspase 3/7 is underlined and the putative cleavage site is marked with an arrow. (C) CEF monolayers are infected with ARV S1133 (lanes
1 and 6) or transfected with empty pCINeo plasmid (lane 2) and with plasmids expressing muNS versions comprising the amino acid residues shown on top of lanes 3–5. The
cells are radiolabeled with [35S]amino acids for 1 h at 16 hpi or for 5 h at 24 h after transfection, lysed with RIPA buffer and the extracts are immunoprecipitated with muNS-
speciﬁc antiserum. Immunoprecipitated proteins are resolved on an 8% tricine–SDS-PAGE gel and protein bands are visualized by autoradiography. (D) The D154A muNS
mutant (lane 1) and the ARV proteins shown on top (lanes 2 and 3) are transiently expressed in CEF cells, either individually (top row) or in combination with D154A (bottom
row). At 24 h after transfection the cells are subjected to immunoﬂuorescence analysis using, as primary antibodies, polyclonal antiserum against muNS (lane 1), ARV cores
(lane 2), and sigmaNS (lane 3). (E) CEF monolayers are transfected with plasmids pCINeo-muNS (lanes 1–3) and pCINeo-D154A (lanes 4–5), and at 18 h post-transfection the
cells in lanes 2, 3 and 5 are incubated for 6 h in the presence of 0.5 μM staurosporine, and the cells in lane 3 are also supplemented with 10 μM Q-VD-OPh. The cells are then
lysed and subjected to Western blot analysis with anti-muNS serum. (F) 35S-radiolabeled in-vitro-synthesized muNS (lane 1) or its D154A point mutant (lane 2) is incubated
for 4 h at 37 1C with extracts from ARV-infected cells. These samples, as well as an extract of ARV-infected CEF immunoprecipitated against muNS (lane 3), are analyzed by
10% SDS-PAGE and autoradiography. The positions of protein markers are indicated on the left and those of ARV nonstructural proteins on the right.
J. Rodríguez-Grille et al. / Virology 462-463 (2014) 49–59 53
cleavage takes place in ARV-infected cells of both avian and
mammalian origin indicates that muNS is a substrate for avian
and mammalian caspases. To assess the role of caspase 3 in muNS
processing we compared muNS-to muNSC conversion in
ARV-infected HeLa and MCF-7 human cells. HeLa is a caspase
3-competent cell line, whereas MCF-7 is a breast cancer cell line
that does not express a functional caspase 3 due to a 125 bp
deletion in exon 3 of the caspase 3 gene (Jänicke, 2009). The
results of the immunoblot analysis shown in Fig. 5A reveal that
muNS-to-muNSC conversion takes place in ARV-infected HeLa
cells (lane 2) and that this conversion is prevented by the
pancaspase inhibitor Q-VD-OPh (lane 3). However, muNS-to-
muNSC conversion did not occur in ARV-infected MCF-7 cells
(lane 5), even when these cells were treated for the last 6 h of
infection with pro-apoptotic staurosporine (lane 6). This result
suggests that caspase 3 or a protease activated by caspase 3 is
directly involved in the cleavage of muNS.
We next examined whether a recombinant muNS protein
puriﬁed from baculovirus-infected insect cells is a substrate for
active caspases 3 and 7 of human origin available commercially.
The samples obtained when muNS was incubated with these
caspases, either in the presence or absence of Q-VD-OPh, as well
as an extract of ARV-infected CEF, were subjected to Western blot
analysis with muNS-speciﬁc antiserum. The results shown in
Fig. 5B reveal that partial muNS-to-muNSC conversion occur in
the samples incubated with caspase 3, and that this conversion is
prevented by the pancaspase inhibitor Q-VD-OPh. Although the
result shown in lane 5 of Fig. 5B appears to suggest that muNS is
not a substrate for caspase 7, a faint band with the same
electrophoretic mobility as muNSC, which disappears in the
presence of Q-VD-OPh, is detected in some caspase 7 incubations
after long exposures of the membrane (not shown).
Distinctive properties of muNS isoforms
We ﬁrst analyzed the capacity of three muNS isoforms to form
inclusions and to recruit other viral proteins to these structures.
The pictures shown in Fig. 6A reveal that both muNS and muNSC,
but not muNSN, collect into globular inclusions when expressed
Fig. 5. Identiﬁcation of the caspase that catalyzes muNS cleavage. (A) Semicon-
ﬂuent monolayers of HeLa (lanes 1–3) and MCF-7 (lanes 4–6) cells are mock-
infected (lanes 1 and 4) or infected with 50 PFU/cell of ARV 1733 (lanes 2, 3, 5 and
6). The cells in lane 3 are incubated with 10 μM Q-VD-OPh from the onset of the
infection and the cells in lane 6 are incubated with 0.5 μM staurosporine during the
last 6 h of infection. At 16 hpi the cells are lysed in RIPA buffer and the resulting cell
extracts are analyzed by Western blotting with muNS-speciﬁc antiserum. (B) 1 μg
of recombinant muNS puriﬁed from baculovirus-infected insect cells (lane 2) is
incubated with 1 unit of either caspase 3 (lanes 3 and 4) or caspase 7 (lanes 5 and
6) for 4 h at 37 1C, in the presence (lanes 4 and 6) or absence (lanes 3 and 5) of
10 μM Q-VD-OPh. These samples, as well as an extract of ARV-infected CEF (lane 1),
are subjected to Western blot analysis using polyclonal anti-muNS serum. The
positions of protein markers are shown on the left and those of nonstructural ARV
proteins on the right.
Fig. 6. Properties of muNS, muNSC and muNSN. (A) Plasmids expressing muNS versions comprising the amino acid residues shown on top are lipofected into CEF
monolayers, and at 20 h post-transfection the cells are subjected to immunoﬂuorescence analysis with muNS-speciﬁc antiserum as primary antibody (green), and
counterstained with DAPI (blue). (B) Plasmids expressing the ARV proteins depicted on the left are transfected into CEF monolayers either individually (lane 1) or together
with plasmids expressing full-length muNS (lane 2) or muNS(155–635). At 20 h post-transfection the cells are processed for immunoﬂuorescence using as primary
antibodies polyclonal antisera against ARV cores (top row) and sigmaNS (bottom row), and counterstained with DAPI (blue). (C) CEF monolayers are mock-infected (lanes
1 and 3) or infected with 10 PFU/cell of ARV S1133 (lanes 2 and 4) for 16 h. The cells are then lysed with TX-buffer, incubated for 10 min on ice and the TX-soluble fraction is
removed (lanes 1 and 2). The plate-attached fraction is then solubilized with RIPA buffer (TX-insoluble fraction; lanes 3 and 4). The two fractions are analyzed by Western
blotting with muNS-speciﬁc antiserum. (D) ARV-infected cells are labeled for 10 min with [35S]amino acids and then incubated in non-radioactive medium for the indicated
chasing times. The cells are subsequently processed as for Fig. 2C and the resulting TX-soluble and -insoluble fractions are immunoprecipitated with muNS-speciﬁc
antiserum. Immunoprecipitated proteins are resolved by electrophoresis on an 8% tricine-SDS-PAGE gel and visualized by autoradiography. Positions of protein markers are
indicated on the left and those of ARV proteins on the right.
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individually in transfected cells. Furthermore, all muNS trunca-
tions containing the intercoil region (residues 477–542) including
muNSC, but not HA-tagged muNSN, collected into inclusions when
co-expressed with muNS (Brandariz-Nuñez et al., 2010a). How-
ever, these results should be taken with caution, since the attached
tag could modify the properties of the proteins. On the other hand,
the immunoﬂuorescent images presented in Fig. 6B show that
muNS, but not muNSC, is able to recruit lambdaA and sigmaNS to
inclusions (compare lanes 2 and 3). This result suggests that the
portion of muNS corresponding to muNSN contains sequences
required for the interaction with each of the two ARV proteins.
We next examined the strength with which muNS and muNSC
associate with ARV factories. For this we compared the capacity of
Triton-X-100-containing buffer (TX) to extract muNS and muNSC
from ARV-infected cells. This buffer has been previously used to
discriminate between soluble and cytoskeleton-associated mam-
malian reovirus proteins, as well as soluble and inclusion-
associated ARV proteins (Mora et al., 1987; Touris-Otero et al.,
2004a). In the ﬁrst approach, mock-infected (Fig. 6C, lanes 1 and 3)
and ARV-infected CEF (Fig. 6C, lanes 2 and 4) were lysed with the
Triton-X-100-containing buffer and the extracts resolved into
TX-soluble (lanes 1 and 2) and TX-insoluble (lanes 3 and 4)
fractions. The resulting samples were subjected to Western blot
analysis with muNS-speciﬁc antiserum. The results revealed that
while similar amounts of muNS were present in the TX-soluble
and -insoluble fractions, most muNSC was extracted by the
TX buffer. In the second approach, ARV-infected cells were pulsed
with [35S]amino acids for 10 min, then chased in nonradioactive
medium for different time periods, and ﬁnally fractionated into
TX-soluble and -insoluble fractions. The samples were immuno-
precipitated with muNS-speciﬁc antiserum and analyzed by 8%
tricine–SDS-PAGE and autoradiography (Fig. 6D). The results
revealed that newly-synthesized muNS and sigmaNS distributed
between the two fractions, with a slightly higher proportion in the
TX-insoluble fraction. In contrast, most muNSC and almost all
muNSN were extracted by the TX buffer at all chasing times. The
reliability of the extracting procedure was evidenced by the
ﬁnding that the structural protein lambdaA coimmunoprecipitated
with muNS exclusively in the TX-insoluble fraction at all chasing
times (lanes 6–8). These ﬁndings indicate that muNS, sigmaNS and
lambdaA associate with ARV factories more tightly than muNSC,
despite that muNSC, but not lambdaA or sigmaNS, collects into
inclusions when expressed individually in transfected cells.
Effect of caspase inhibition on ARV replication and spread
It is of interest to determine the role that muNS processing
plays on ARV replication. In the absence of an established reverse
genetics system for ARV that would allow us to generate a
recombinant virus that expresses an uncleavable muNS protein,
like D154A, we examined the effect of Q-VD-OPh on ARV replica-
tion in CEF cells, since this compound had been shown to block
both apoptosis and muNS processing. The Western blot shown in
Fig. 7A reveals that although the presence of the inhibitor from the
onset of the infection completely blocks muNS processing, it does
not signiﬁcantly alter the intracellular concentration of the ARV
Fig. 7. Effect of Q-VD-OPh on ARV replication and dissemination. (A) CEF monolayers are mock-infected (M) or infected with 10 PFU/cell of ARV S1133 (I), in the presence
(þQ) or absence of 10 μM Q-VD-OPh. The cells are processed for immunoblotting at 16 hpi and the membranes are probed with rabbit polyclonal antibodies against both
muNS and sigmaNS. The positions of protein markers are indicated on the left and those of the non-structural ARV proteins on the right. (B) CEF monolayers are infected with
0.1 PFU/cell of ARV S1133, and the production of both total virus (intracellularþculture medium; ﬁlled bars) and released virus (cultured medium; open bars) is determined
after 24 h of infection by plaque assay on CEF monolayers. (C) Plaque pictures obtained by titrating a stock of ARV S1133 on CEF monolayers in the absence (lane 1) or
presence (lane 2) of 10 μM Q-VD-OPh. The pictures in lane 1 correspond to a 106 dilution and the ones in lane 2 to 105 dilution of the same virus stock. Plaques of two
different plaque assays are shown.
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nonstructural protein sigmaNS. This result indicates that apoptosis
and muNS processing do not have signiﬁcant effects on ARV gene
expression and on stages of the virus life cycle prior to gene
expression. Furthermore, the inhibitor did not signiﬁcantly change
the production of infective ARV particles, as determined by a virus
plaque assay (Fig. 7B, total virus), indicating that both apoptosis
and muNS processing are not required for the production of
infective progeny in cultured cells.
We next investigated the effect of Q-VD-OPh on ARV release by
titrating the infectious viral particles released into the incubation
medium. The results showed that virus release was drastically
reduced when the infected cells were incubated in the presence of
Q-VD-OPh (Fig. 7B, released virus), suggesting that ARV-induced
apoptosis enhances dissemination of progeny reovirions from
infected cells. This suggestion was further supported by our
ﬁnding that the presence of Q-VD-OPh during plaque assay of an
ARV stock, where the agar overlay limits virus dissemination to
neighboring cells, caused a signiﬁcant reduction in the size of the
viral plaques (Fig. 7C), suggesting that the inhibitor reduces cell-
to-cell viral spread over the different rounds of replication, release
and re-infection that occur during plaque formation.
Discussion
Activation of programmed cell death is one of the ﬁrst protec-
tive defences setup by the host cell to restrict viral ampliﬁcation
and spread. When triggered early in infection apoptosis may limit
both the time and the cellular machinery available for virus
replication. Therefore, it is not surprising that many viruses try
to overcome the apoptotic threat by using a battery of different
strategies and by expressing a variety of antiapoptotic products
aimed to block or delay the induction of apoptosis (Galluzzi et al.,
2010). However, other viruses induce apoptosis actively at late
stage of infection to facilitate virus release and spread with limited
induction of inﬂamatory and immune host responses (Teodoro and
Branton, 1997). The results shown in Fig. 2E conﬁrm previous
ﬁndings from our laboratory that ARV infection triggers apoptosis
in cultured cells at an early stage of the viral life cycle (Labrada et
al., 2002), yet the results of this study demonstrate that early
apoptosis triggering does not have adverse effects on either ARV
gene expression or infectious progeny production. These appar-
ently conﬂicting results can be reconciled considering that ARV
has a short replication time (Benavente and Martinez-Costas,
2006), which would allow the virus to proceed its life cycle
successfully until completion and to reach a satisfactory intracel-
lular production of progeny viral particles before the infected cell
dies or is severely damaged by the execution of apoptosis.
A growing number of viruses have been documented to take
advantage of apoptosis induction and caspase activation to pro-
mote their own replication. For instance, viruses as diverse as
mammalian reovirus, human astrovirus, measles virus, porcine
circovirus 2, African swine fever virus, bovine herpesvirus 1,
coronavirus, inﬂuenza virus and the Moscow strain of Ectromelia
virus, all have been reported to usurp apoptosis for facilitating the
release of progeny viral particles from infected cells (Best, 2008;
Galluzzi et al., 2010). The results of the present study suggest that
ARV should be included in that list, since this virus activates rather
than suppress caspases and this activation is necessary for efﬁcient
virus release and spread. On the other hand, many apoptosis-
inducing viruses express proteins that are processed by caspases to
generate cleavage products with novel properties, ranging from
apoptosis downregulation to enhancement or attenuation of viral
replication (Richard and Tulasne, 2012). Still, the functional con-
sequences of many protein caspase cleavages remain elusive so far,
yet the conservation of caspase targets in many viral proteins and
the stability of their processed products suggest that caspase
cleavage of viral polypeptides can constitute an evolutionary
advantage that beneﬁts virus replication. In this study we have
provided compelling evidence that caspases activated during ARV-
induced apoptosis catalyze the cleavage of ARV nonstructural
muNS protein to produce the 17-kDa N-terminal peptide muNSN
and the 55-kDa C-terminal protein muNSC. In the literature to
date, there are several examples of other non-structural viral
proteins that are caspase targets, like the NS1 protein of Aleutian
mink disease parvovirus, the NS5A protein of hepatitis C virus, the
NS10 protein of Japanese encephalitis virus, and the EIA protein of
adenovirus 12 (Best et al., 2003; Grand et al., 2002; Satoh et al.,
2000; Sun et al., 2012). We also observed that a substantial
amount of full-length muNS remains uncleaved both in infected
cells and after 6 h of incubation with recombinant caspase 3,
implying that caspase-catalyzed muNS cleavage is a regulated
process, as has been reported for several cellular and viral proteins
(Best et al., 2003; Chaudhry et al., 2012; Cheng et al., 2010;
Mashima et al., 1999; Sun et al., 2012). Incomplete processing of
a precursor viral protein could be a strategy to reduce the activity
of the intact protein or it could be used to increase the protein
repertoire encoded by size-limited viral genomes, thus generating
cleaved viral products with novel properties/activities.
That avian and mammalian reoviruses use different mechan-
isms to express their muNSC isoforms (Busch et al., 2011), and that
both the muNS precursor and its truncated forms coexist in avian/
mammalian reovirus-infected cells suggest that there should be
distinct functional roles for both the precursor and its truncated
proteins. It should be noted however that avian and mammalian
reovirus muNSC proteins display different properties. Thus, while
mammalian reovirus muNSC still maintains its precursor's ability
to associate with the major core protein lambda1 (Miller et al.,
2010), this ability is not shared by its ARV counterpart (Fig. 6B),
because sequences of ARV muNS required for binding to lambdaA
are lacking in muNSC. It has been reported that the release of
astrovirus from infected cells depends on both the processing of
the capsid precursor polypeptide VP90 and the activities of
executioner caspases (Banos-Lara and Mendez, 2010). Accordingly,
the possibility exists that muNS processing is required for
enhanced release and dissemination of ARV, although it is unlikely,
since apoptosis has also been reported to promote the release of
mammalian reovirus from infected cells without enhancing the
production of its muNSC protein (Marcato et al., 2007). In the
absence of an established reverse genetics system for avian
reoviruses, the consequences of muNS cleavage on viral replication
and spread remain unclear.
Despite the facts that ARV muNSC is able to form inclusions
when expressed in isolation and that it collects into inclusions
when co-expressed with muNS (Brandariz-Nuñez et al., 2010b),
muNSC associates with factories of infected cells more weakly
than full-length muNS, sigmaNS or lambdaA, as evidenced by
extraction with TX buffer (Fig. 6C and D). This observation suggests
that ARV factories are complex structures formed by a diverse
array of protein–protein and protein–RNA interactions and that
these entities are much more complex than muNS-derived inclu-
sions. This is supported by our observation that the inclusions
formed by expressing muNS versions in baculovirus-infected
insect cells can be easily puriﬁed (Brandariz-Nuñez et al., 2010a),
whereas we are unable to purify the factories formed in ARV-
infected cells.
The results shown in Fig. 5 demonstrate that muNS is a
substrate for mammalian caspase 3, yet the absence of both
commercial recombinant caspases of avian origin and caspase
3-deﬁcient avian cells does not allow us to identify the avian
caspase that catalyzes ARV muNS cleavage in infected avian cells.
Nevertheless, this cleavage is probably catalyzed by an avian caspase
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3-like protease, since caspase sequences and targets are highly
conserved in different species (Sakamaki and Satou, 2009), and
since we found both that caspase 3/7 is active in ARV-infected
avian cells and that muNS-to-muNSC processing is promoted by
the caspase 3 activator staurosporine (Chae et al., 2000). The
presence of a caspase 3/7 consensus sequence (151DSPD↓A155)
within the muNS cleavage region allowed us to map the muNS
cleavage site between residues Asp-154 and Ala-155, by using site-
directed mutagenesis. This ﬁnding suggests that this region of
muNS is placed in a ﬂexible and exposed loop accessible to
caspases. Interestingly, the caspase 3/7 consensus sequence found
in ARV S1133 muNS is not fully conserved among avian reoviruses
isolated from chickens, since it is only present in 8 isolates, and in
one quail isolate, but not in other 9 chicken isolates. Thus, in the
muNS protein from 4 chicken isolates Asp-151 is replaced by His,
while in the protein from another 5 isolates Asp-151 and Ser-152
are replaced by His and Glu, respectively (Fig. 8). If cleavage of
these “nonconsensus” ARV muNS proteins still occurs between
Asp-154 and Ala-155, it would imply that accessibility is more
important than the presence of speciﬁc amino acids at positions
3 and 4 of the caspase consensus sequence, which is in agreement
with previous reports indicating that caspases do not have a strict
requirement for positions 2–4 of the consensus cleavage site
(Timmer and Salvesen, 2007; Thornberry et al., 1997). Curiously,
the muNS protein encoded by both duck and goose reoviruses
does not contain a caspase 3/7 consensus sequence spanning
residues 151–155, because Asp-154 is replaced by a Gly residue.
However, these muNS proteins contain two putative caspase
targets, one spanning residues 142–146 (142GTMDA146), and the
other comprising residues 156–160 (156SVPDV160). Surprisingly,
the former caspase target is also present in the muNS protein from
four chicken isolates (Fig. 8). It should be of interest to check
whether duck/goose reoviruses induce apoptosis, whether the
muNS protein of these viruses is cleaved in infected cells and
whether its cleavage takes place at one or both of these caspase
consensus sequences. Nevertheless, the presence of speciﬁc resi-
dues in the muNS 140–177 region could serve to assign a poultry
reovirus as an avian/quail or a goose/duck reovirus. Thus, the
muNS from reoviruses of avian/quail origin has leucine in position
144, alanine or valine in 150, aspartic acid in 154, cysteine in 156
and valine in 159, whereas the muNS from reoviruses of duck/
goose origin has methionine, glycine, glycine and aspartic acid in
those positions.
Methods
Cells, viruses, antibodies and reagents
Primary cultures of CEFs were prepared from 9- to 10-day-old
chicken embryos and grown in monolayers in medium 199
supplemented with 10% tryptose phosphate broth and 5% calf
serum. Avian DF-1, human HeLa and MCF-7, and monkey Vero cell
lines, all were grown in monolayers in Dulbecco's modiﬁed Eagle's
medium (DMEM; Invitrogen) supplemented with 10% fetal bovine
serum (FBS). MCF-7 cells were a kind gift from María Dolores
Blanco (Universidad Complutense de Madrid). Sf9 cells were
grown in suspension culture in serum-free Sf-900 II media at
27 1C. Strains S1133, 1733 and 2408 of avian reovirus were grown
in semiconﬂuent monolayers of primary CEFs. Conditions for
growing and titrating these viruses have been described pre-
viously (Grande and Benavente, 2000). The recombinant baculo-
virus AcNPV-S1133-muNS was grown in Sf9 cells as previously
described (Brandariz-Nuñez et al., 2010b).
Rabbit polyclonal sera against ARV S1133 reovirions and cores,
as well as ARV S1133 proteins muNS and sigmaNS were raised in
our laboratory (Touris-Otero et al., 2004b). Monoclonal anti-
gamma histone H2A.X (phospho S139) antibody was purchased
from Abcam plc. Rabbit anti-actin polyclonal antibody was
purchased from Santa Cruz Biotechnology. Peroxidase-conjugated
Fig. 8. Alignment of the deduced amino acid sequences of the muNS 140–177 region from different poultry reoviruses. Sources of the host birds, virus strains, deduced
amino acid sequences of the muNS region 140–177 and protein accession numbers are indicated. Putative consensus caspase cleavage sequences are boxed.
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goat anti-rabbit antibody was purchased from Sigma. Pancaspase
inhibitors Z-VAD-FMK and Q-VD-OPh were from Calbiochem.
Caspases 3 and 7 were from Enzo Life Science (Cat. # C-3: ALX-
201-059; C-7: ALX-201-061-U025). All other reagents were pur-
chased from Sigma.
Viral infections and protein analysis
Semiconﬂuent monolayers of cells were infected with 10 PFU/
cell of ARVs for the times indicated for each experiment. In all
experiments, except for some of Fig. 1 and those of Fig. 5A, CEF cell
monolayers were infected with the ARV S1133. For metabolic
radiolabeling, the cultured medium was removed and the cells
were incubated for the indicated times in methionine/cysteine-
free medium containing 100 μCi/ml of [35S]methionine–cysteine.
For immunoprecipitation and Western blot analyses the cells were
lysed in RIPA buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1%
NP40, 0.5% DOC, 0.1% SDS, supplemented with “Complete protease
inhibitor cocktail” from Roche Diagnostics), and muNS-derived
proteins were detected with a muNS-speciﬁc antiserum (Touris-
Otero et al., 2004b).
To isolate TX-soluble and -insoluble fractions, 2106 cells were
lysed in 200 μl of TX buffer (10 mM Pipes pH 6.8, 3 mM MgCl2,
100 mM KCl, 300 mM sucrose, 1% Triton X-100, supplemented
with “Complete protease inhibitor cocktail” from Roche Diagnos-
tics) and the soluble fraction was removed. The plates were
washed again with TX buffer and the insoluble fraction that
remained attached to the plates was directly solubilized in
200 μl of RIPA buffer (Touris-Otero et al., 2004a). For pulse-chase
analysis, mock-infected and reovirus-infected cells were incubated
for 2 h at 12 h p.i. in medium lacking methionine and cysteine, and
then incubated for 10 min in the same medium supplemented
with 500 μCi/ml [35S]amino acids. The cells were chased for the
indicated times in non-radioactive medium supplemented with an
excess of nonradiolabelled methionine and cysteine. Infection of
Sf9 insect cells with the recombinant baculovirus AcNPV-S1133-
muNS and puriﬁcation of recombinant muNS have already been
described (Brandariz-Nuñez et al., 2010b).
Plasmid construction and cell transfection
The construction of recombinant plasmids expressing full-
length ARV S1133 muNS, GFP-muNS, and the aminoterminal
truncations comprising muNS residues 84-635, 127–635 and
140–635 has already been described (Brandariz-Nuñez et al.,
2010b). Plasmid pCINeo-muNS was used as template to generate
constructs expressing the following proteins. The D154A muNS
point mutant was generated with the QuikChange site-directed
mutagenesis kit (Stratagene), according to the manufacturer's
speciﬁcations. The forward primer was: 50–CCACCGCTGATTCC-
CCCGCTGCCTGCGTCCCAGTCACC–30; and the reverse primer was:
50–GGTGACTGGGACGCAGGCAGCGGGGGAATCAGCGGTGG–30. To gen-
erate the construct expressing muNS(1–154), the forward primer
was: 50–GCGGAATTCATCATGGCGTCAACCAAGTGG–30; and the reverse
primer was: 50–GCGTCTAGATTAATCGGGGGAATCAGCGGTGG–30. To
generate the construct expressing muNS (155–635), the forward
primer was: 50–GCGGAATTCATCATGGCCTGCGTCCCAGTC–30; and
the reverse primer was: 50–GCGTCTAGATCACAGATCATCCAC-
CAATTCTTC–30. The correctness of the recombinant plasmids was
conﬁrmed by nucleotide sequencing.
Transfection of preconﬂuent cell monolayers was done using
Lipofectamine Plus reagent (Invitrogen) following the manufac-
turer's instructions, with 1 μg of DNA per well of a 12-well dish.
Transfected cells were incubated at 37 1C for 24 h, unless other-
wise stated.
Indirect immunoﬂuorescence microscopy
Cell monolayers grown on coverslips were infected or trans-
fected as indicated in the ﬁgure legends. At the indicated times,
the monolayers were washed twice with PBS and ﬁxed in
paraformaldehyde for 15 min at 4 1C. Fixed cells were washed
twice with PBS, incubated for 10 min in permeabilizing buffer
(0.1% Triton X-100 in PBS), incubated 20 min with blocking buffer
(2% BSA in PBS), and then incubated for 1 h at room temperature
with primary antibodies diluted in blocking buffer. The cells were
washed three more times with PBS and then incubated with
secondary antibodies and DAPI (4,6-diamidino-2-phenylindole)
for 1 h at room temperature. Coverslips were then washed six
times with PBS and mounted on glass slides. Images were
obtained with an Olympus DP-71 digital camera mounted on an
Olympus BX51 ﬂuorescence microscope. Images were processed
with Adobe Photoshop (Adobe Systems).
in vitro transcription and translation
The recombinant plasmids used as templates were linearized
with NotI, puriﬁed by extraction with phenol/chloroform, precipi-
tated with ethanol and resuspended in sterile water at a ﬁnal
concentration of 1 mg/ml. in vitro transcription from the T7
promoter was performed by using a RiboMAX Large Scale RNA
Production System (Promega). in vitro translation was carried out
by using a Rabbit Reticulocyte Lysate System (nuclease-treated;
Promega) following the manufacturer's instructions, for 90 min at
30 1C in the presence of 50 mg/ml RNA and 0.4 mCi/ml [35S]
methionine (Hartmann analytic KSM-01).
Intracellular caspase activity and in vitro protease cleavage assays
The intracellular activity of caspases 3/7 was determined with
the Caspase-Glos 3/7 Assay kit from Promega, following the
manufacturer's instructions. in vitro caspase cleavage assays were
performed by mixing 1 μg of muNS puriﬁed from baculovirus-
infected insect cells, as described previously (Brandariz-Nuñez et
al., 2010a), with 1 unit of recombinant caspase in 10 μl of caspase
buffer (20 mM Hepes pH 7.4; 100 mM NaCl; 0.05% NP-40). In some
samples 10 μM of the pancaspase inhibitor Q-VD-OPh was also
included. Mixtures were incubated for 4 h a 37 1C, mixed with 5 μl
of 3X Laemmli electrophoresis sample buffer and boiled for 5 min
at 100 1C. Cleavage of muNS was analyzed by Western blotting.
To evaluate the capacity of extracts of ARV-infected cells to
promote muNS cleavage, extracts from mock-infected and infected
cells were prepared as follows. Samples of 2107 CEF cells, mock-
infected or infected with 0.1 PFU/ml of ARV S1133, in the presence
or absence of 10 μM Q-VD-OPh, were washed twice with PBS at
24 hpi and overlayed with 1 ml of caspase buffer. The cells were
then collected by scrapping and lysed by one cycle of freezing and
thawing. A typical protease cleavage assay was performed by
mixing 5 μl of cell extract with 5 μl of reticulocyte lysate contain-
ing 35S-radiolabeled muNS or its D154A mutant. Samples were
incubated for 2 h at 37 1C, then supplemented with 5 μl of 3X
Laemmli sample buffer and boiled for 5 min at 100 1C. Processing
of muNS was monitored by SDS-PAGE and autoradiography.
Acknowledgments
We would like to thank Rebeca Menaya for technical assistance
and other members of our laboratory for helpful discussions on
the manuscript. We also thank Laboratorios MSD España (Sala-
manca, Spain) for providing pathogen-free embryonated eggs. This
work was funded by grants from the Ministerio de Economia
J. Rodríguez-Grille et al. / Virology 462-463 (2014) 49–5958
Competitividad (BFU2010-22228) and from the Xunta de Galicia
(CN 2012/018).
References
Bacon, L.D., Hunt, H.D., Cheng, H.H., 2000. A review of the development of chicken
lines to resolve genes determining resistance to diseases. Poult. Sci. 79,
1082–1093.
Banos-Lara, M.R., Mendez, E., 2010. Role of individual caspases induced by
astrovirus on the processing of its structural protein and its release from the
cell by a non-lytic mechanism. Virology 401, 322–332.
Benavente, J., Martinez-Costas, J., 2006. Early steps in avian reovirus morphogen-
esis. Curr. Top. Microbiol. Immunol. 309, 67–85.
Benavente, J., Martinez-Costas, J., 2007. Avian reovirus: structure and biology. Virus
Res. 123, 105–119.
Best, S.M., 2008. Viral subversion of apoptotic enzymes: escape from death row.
Annu. Rev. Microbiol. 62, 171–192.
Best, S.M., Shelton, J.F., Pompey, J.M., Wolﬁnbarger, J.B., Bloom, M.E., 2003. Caspase
cleavage of the non-structural protein NS1 mediates replication of Aleutian
mink disease parvovirus. J. Virol. 77, 5305–5312.
Bodelon, G., Labrada, L., Martinez-Costas, J., Benavente, J., 2001. The avian reovirus
genome segment S1 is a functionally tricistronic gene that expresses one
structural and two nonstructural proteins in infected cells. Virology 290,
181–191.
Brandariz-Nuñez, A., Menaya-Vargas, R., Benavente, J., Martinez-Costas, J., 2010a. A
versatile molecular tagging method for targeting proteins to avian reovirus
muNS inclusions. Use in protein immobilization and puriﬁcation. PLoS ONE 5,
e13961.
Brandariz-Nuñez, A., Menaya-Vargas, R., Benavente, J., Martinez-Costas, J., 2010b.
Avian reovirus muNS protein forms homo-oligomeric inclusions in a
microtubule-independent fashion, which involves speciﬁc regions of its C
terminal domain. J. Virol. 84, 4289–4301.
Busch, L.K., Rodriguez-Grille, J., Ignacio Casal, J., Martinez-Costas, J., Benavente, J.,
2011. Avian and mammalian reoviruses use different molecular mechanisms to
synthesize their μNS isoforms. J. Gen. Virol. 92, 2566–2574.
Caserta, T.M., Smith, A.N., Gultice, A.D., Reedy, M.A., Brown, T.L., 2003. Q-VD-OPh, a
broad spectrum caspase inhibitor with potent antiapoptotic properties. Apop-
tosis 8, 345–352.
Chae, H-J., Kang, J-S., Byun, J-O., Han, K-S., Kim, D-U., Oh, S-E., Kim, H-M., Chae, S-
W., Kim, H-R., 2000. Molecular mechanism of staurosporine-induced apoptosis
in osteoblasts. Pharmacol. Res. 42, 373–381.
Chaudhry, P., Singh, M., Parent, S., Asselin, E., 2012. Prostate apoptosis response 4
(Par-4), a novel substrate of caspase 3 during apoptosis activation. Mol. Cell
Biol. 32, 826–839.
Cheng, F., Chen, A.Y., Best, S.M., Bloom, M.E., Pintel, D., Qiu, J., 2010. The capsid
proteins of Aleutian mink disease virus activate caspases and are speciﬁcally
cleaved during infection. J. Virol. 84, 2687–2696.
Clem, R.J., 2007. Baculoviruses and apoptosis: a diversity of genes and responses.
Curr. Drug Targets 8, 1069–1074.
Clem, R.J., Fechheimer, M., Miller, L.K., 1991. Prevention of apoptosis by a
baculovirus gene during infection of insect cells. Science 254, 1388–1390.
Cook, P.J., Ju, B.G., Telese, F., Wang, X., Glass, C.K., Rosenfeld, M.G., 2009. Tyrosine
dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature
458, 591–596.
Galluzzi, L., Kepp, O., Morselli, E., Vitale, I., Senovilla, L., Pinti, M., Zitvogel, L.,
Kroemer, G., 2010. Viral strategies for the evasion of immunogenic cell death. J.
Intern. Med. 267, 526–542.
Grand, R.J.A., Schmeiser, K., Gordon, E.M., Zhang, X., Gallimore, P.H., Turnell, A.S.,
2002. Caspase-mediated cleavage of adenovirus early region 1A proteins.
Virology 301, 255–271.
Grande, A., Benavente, J., 2000. Optimal conditions for the growth, puriﬁcation and
storage of the avian reovirus S1133. J. Virol. Methods 85, 43–54.
Jänicke, R.U., 2009. MCF-7 breast carcinoma cells do not express caspase-3. Breast
Cancer Res. Treat. 117, 219–221.
Ji, W.T., Lin, F.L., Wang, Y.C., Shih, W.L., Lee, L.H., Liu, H.J., 2010. Intracellular cleavage
of sA protein of avian reovirus. Virus Res. 149, 71–77.
Jones, R.C., 2000. Avian reovirus infections. Rev. Sci. Tech. 19, 614–625.
Kong, B.W., Lee, J.Y., Bottje, W.G., Lassiter, K., Lee, J., Foster, D.N., 2011. Genome-wide
differential gene expression in immortalized DF-1 chicken embryo ﬁbroblast
cell line. BMC Genomics 12, 571.
Kuželová, K., Grebeňová, D., Brodská, B., 2011. Dose-dependenteffects of the caspase
inhibitor Q-VD-OPh on different apoptosis-related processes. J. Cell Biochem.
112, 3334–3342.
Labrada, L., Bodelon, J., Viñuela, J., Benavente, J., 2002. Avian reoviruses cause
apoptosis in cultured cells: viral uncoating, but not viral gene expression, is
required for apoptosis induction. J. Virol. 76, 7932–7941.
Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D., Lee, P.W., 2007. Ras transformation
mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity,
and apoptosis-dependent release. Mol. Ther. 15, 1522–1530.
Mashima, T., Naito, M., Tsuruo, t., 1999. Caspase-mediated cleavage of cytoskeletal
actine plays a positive role in the process of morphological apoptosis. Oncogene
18, 2423–2430.
Miller, C.L., Arnold, M.M., Broering, T.J., Hastings, C.E., Nibert, M.L., 2010. Localiza-
tion of mammalian orthoreovirus proteins to cytoplasmic factory-like struc-
tures via nonoverlapping regions of μNS. J. Virol. 84, 867–882.
Mora, M., Partin, K., Bhatia, M., Partin, J., Carter, C., 1987. Association of avian
reovirus proteins with the structural matrix of infected cells. Virology 159,
265–277.
Richard, A., Tulasne, D., 2012. Caspase cleavage of viral proteins, another way for
viruses to make the best of apoptosis. Cell Death Dis. 3, e277.
Sakamaki, K., Satou, Y., 2009. Caspases: evolutionary aspects of their functions in
vertebrates. J. Fish Biol. 74, 727–753.
Satoh, S., Hirota, M., Noguchi, T., Hijikata, M., Handa, H., Shimotonot, k., 2000.
Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like
protease(s) in mammalian cells. Virology 270, 476–487.
Schägger, H., 2006. Tricine-SDS-PAGE. Nat. Protoc. 1, 16–22.
Sun, J., Yu, Y., Deubel, V., 2012. Japanese encephalitis virus NS10 protein depends on
pseudoknot secondary structure and is cleaved by caspase during virus
infection and cell apoptosis. Microbes Infect. 14, 930–940.
Teodoro, J.G., Branton, P.E., 1997. Regulation of apoptosis by viral gene products. J.
Virol. 71, 1739–1746.
Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper, D.M., Timkey, T., Garcia Calvo, M.,
Houtzager, V.M., Nordstrom, P.A., Roy, S., Vaillancourt, J.P., Chapman, K.T.,
Nicholson, D.W., 1997. A combinatorial approach deﬁnes speciﬁcities of
members of the caspase family and granzyme B. Functional relationships
established for key mediators of apoptosis. J. Biol. Chem. 272, 17907–17911.
Timmer, J.C., Salvesen, G.S., 2007. Caspase substrates. Cell Death Differ. 14, 66–72.
Touris-Otero, F., Cortez-San Martin, M., Martinez-Costas, J., Benavente, J., 2004a.
Avian reovirus morphogenesis occurs within viral factories and begins with the
selective recruitment of sNS and λA to μNS inclusions. J. Mol. Biol. 341,
361–374.
Touris-Otero, F., Martinez-Costas, J., Vakharia, V.N., Benavente, J., 2004b. Avian
reovirus nonstructural protein μNS forms viroplasm-like inclusions and recruits
protein sNS to these structures. Virology 319, 94–106.
van der Heide, L., 2000. The history of avian reovirus. Avian Dis. 44, 638–664.
Varela., R., Martinez-Costas, J., Mallo, M., Benavente, J., 1996. Intracellular post-
translational modiﬁcations of S1133 avian reovirus proteins. J. Virol. 70,
2974–2981.
Yuan, J., Adamski, R., Chen, J., 2010. Focus on histone variant H2AX: to be or not to
be. FEBS Lett. 584, 3717–3724.
J. Rodríguez-Grille et al. / Virology 462-463 (2014) 49–59 59
